| Literature DB >> 32095773 |
Philip Coran1, Jennifer C Goldsack2,3, Cheryl A Grandinetti4, Jessie P Bakker5, Marisa Bolognese6, E Ray Dorsey7, Kaveeta Vasisht4, Adam Amdur8, Christopher Dell9, Jonathan Helfgott10, Matthew Kirchoff11, Christopher J Miller12, Ashish Narayan13, Dharmesh Patel14, Barry Peterson15, Ernesto Ramirez16, Drew Schiller17, Thomas Switzer18, Liz Wing19, Annemarie Forrest2, Aiden Doherty20,21.
Abstract
Mobile technologies offer the potential to reduce the costs of conducting clinical trials by collecting high-quality information on health outcomes in real-world settings that are relevant to patients and clinicians. However, widespread use of mobile technologies in clinical trials has been impeded by their perceived challenges. To advance solutions to these challenges, the Clinical Trials Transformation Initiative (CTTI) has issued best practices and realistic approaches that clinical trial sponsors can now use. These include CTTI recommendations on technology selection; data collection, analysis, and interpretation; data management; protocol design and execution; and US Food and Drug Administration submission and inspection. The scientific principles underpinning the clinical trials enterprise continue to apply to studies using mobile technologies. These recommendations provide a framework for including mobile technologies in clinical trials that can lead to more efficient assessment of new therapies for patients.Entities:
Keywords: Clinical trials; Mobile technologies; Regulatory approval; Wearable sensors
Year: 2019 PMID: 32095773 PMCID: PMC7011727 DOI: 10.1159/000503957
Source DB: PubMed Journal: Digit Biomark ISSN: 2504-110X